MA30706B1 - Derives du tartrate destines a etre utilises comme inhibiteurs du facteur de coagulation ixa. - Google Patents

Derives du tartrate destines a etre utilises comme inhibiteurs du facteur de coagulation ixa.

Info

Publication number
MA30706B1
MA30706B1 MA31699A MA31699A MA30706B1 MA 30706 B1 MA30706 B1 MA 30706B1 MA 31699 A MA31699 A MA 31699A MA 31699 A MA31699 A MA 31699A MA 30706 B1 MA30706 B1 MA 30706B1
Authority
MA
Morocco
Prior art keywords
coagulation factor
inhibitors
ixa
tartrate derivatives
tartrate
Prior art date
Application number
MA31699A
Other languages
English (en)
French (fr)
Inventor
Henning Steinhagen
Markus Follmann
Jochen Goerlitzer
Herman Schreuder
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA30706B1 publication Critical patent/MA30706B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/60—Two oxygen atoms, e.g. succinic anhydride
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/16—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58—One oxygen atom, e.g. butenolide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MA31699A 2006-09-13 2009-03-06 Derives du tartrate destines a etre utilises comme inhibiteurs du facteur de coagulation ixa. MA30706B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006042927 2006-09-13

Publications (1)

Publication Number Publication Date
MA30706B1 true MA30706B1 (fr) 2009-09-01

Family

ID=38720737

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31699A MA30706B1 (fr) 2006-09-13 2009-03-06 Derives du tartrate destines a etre utilises comme inhibiteurs du facteur de coagulation ixa.

Country Status (22)

Country Link
US (1) US8263621B2 (cg-RX-API-DMAC7.html)
EP (1) EP2069288B1 (cg-RX-API-DMAC7.html)
JP (1) JP5249225B2 (cg-RX-API-DMAC7.html)
KR (1) KR20090053813A (cg-RX-API-DMAC7.html)
CN (1) CN101516833B (cg-RX-API-DMAC7.html)
AR (1) AR062744A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007297012B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0716778A2 (cg-RX-API-DMAC7.html)
CA (1) CA2663543A1 (cg-RX-API-DMAC7.html)
CL (1) CL2007002651A1 (cg-RX-API-DMAC7.html)
CO (1) CO6220943A2 (cg-RX-API-DMAC7.html)
IL (1) IL197505A0 (cg-RX-API-DMAC7.html)
MA (1) MA30706B1 (cg-RX-API-DMAC7.html)
MX (1) MX2009001990A (cg-RX-API-DMAC7.html)
MY (1) MY148254A (cg-RX-API-DMAC7.html)
NO (1) NO20091106L (cg-RX-API-DMAC7.html)
NZ (1) NZ575604A (cg-RX-API-DMAC7.html)
RU (1) RU2446160C2 (cg-RX-API-DMAC7.html)
TW (1) TWI406852B (cg-RX-API-DMAC7.html)
UY (1) UY30586A1 (cg-RX-API-DMAC7.html)
WO (1) WO2008031508A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200900806B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101209976B (zh) * 2006-12-29 2012-01-11 中国人民解放军军事医学科学院毒物药物研究所 取代的酒石酸衍生物及其用于制备β-分泌酶抑制剂的用途
AU2009322342A1 (en) 2008-12-05 2011-06-30 Merck Sharp & Dohme Corp. Morpholinone compounds as factor IXa inhibitors
US8987242B2 (en) 2008-12-05 2015-03-24 Merck Sharp & Dohme Corp. Morpholinone compounds as factor IXA inhibitors
CN107973809B (zh) * 2010-02-11 2023-06-30 百时美施贵宝公司 作为因子xia抑制剂的大环类
WO2015160636A1 (en) 2014-04-16 2015-10-22 Merck Sharp & Dohme Corp. Factor ixa inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3731542A1 (de) * 1987-09-17 1989-03-30 Schering Ag Neue dicarbonsaeure-bis(3,5-dicarbamoyl-2,4,6-triiod-anilide), verfahren zu deren herstellung sowie diese enthaltende roentgenkontrastmittel
RU2043344C1 (ru) * 1991-05-20 1995-09-10 Курский Государственный Медицинский Институт N-2-(1- r1-5-r2-6-r3- бензимидазолил)сукцинаминовые кислоты, проявляющие нейролептическую, антигипоксическую и антиаритмическую активность
CA2159649A1 (en) 1993-03-29 1994-10-13 Queen's University At Kingston Anticoagulant compounds
US6642252B2 (en) 2000-11-07 2003-11-04 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
DE10104598A1 (de) * 2001-02-02 2002-08-08 Boehringer Ingelheim Pharma Carbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel
US20020151595A1 (en) 2001-02-02 2002-10-17 Ries Uwe Joerg Carboxylic acid amides having antithrombotic activity
US7122559B2 (en) 2003-02-11 2006-10-17 Bristol-Myers Squibb Company Phenylglycine derivatives useful as serine protease inhibitors
US7638513B2 (en) * 2004-06-02 2009-12-29 Schering Corporation Compounds for the treatment of inflammatory disorders

Also Published As

Publication number Publication date
TWI406852B (zh) 2013-09-01
NZ575604A (en) 2011-12-22
US8263621B2 (en) 2012-09-11
AU2007297012A1 (en) 2008-03-20
MX2009001990A (es) 2009-03-06
CN101516833A (zh) 2009-08-26
AU2007297012B2 (en) 2011-12-22
EP2069288A1 (de) 2009-06-17
HK1137419A1 (en) 2010-07-30
CL2007002651A1 (es) 2008-02-08
JP5249225B2 (ja) 2013-07-31
US20090233961A1 (en) 2009-09-17
NO20091106L (no) 2009-06-09
KR20090053813A (ko) 2009-05-27
JP2010503624A (ja) 2010-02-04
AR062744A1 (es) 2008-12-03
BRPI0716778A2 (pt) 2014-04-22
ZA200900806B (en) 2009-12-30
IL197505A0 (en) 2009-12-24
CO6220943A2 (es) 2010-11-19
CN101516833B (zh) 2013-04-03
CA2663543A1 (en) 2008-03-20
EP2069288B1 (de) 2014-03-26
UY30586A1 (es) 2008-05-02
RU2446160C2 (ru) 2012-03-27
TW200829557A (en) 2008-07-16
MY148254A (en) 2013-03-29
RU2009113616A (ru) 2010-10-20
WO2008031508A1 (de) 2008-03-20

Similar Documents

Publication Publication Date Title
MA30707B1 (fr) DERIVES D'ISOSERINE DESTINES A ETRE UTILISES COMME INHIBITEURS DU FACTEUR DE COAGULATION Ixa.
TN2009000128A1 (en) Dihydropyridine derivatives useful as protein kinase inhibitors
EA200802213A1 (ru) Способы лечения заболеваний крови
TW200510333A (en) Benzimidazole compounds
WO2004089286A3 (en) Novel compounds and compositions as protein kinase inhibitors
NO20084652L (no) Deazapuriner anvendelige som inhibitorer av januskinaser
MXPA06011327A (es) Azaindoles utiles como inhibidores de jak y otras proteinas cinasas.
TN2009000163A1 (en) Compounds and compositions as protein kinase inibitors
EA201070607A1 (ru) Гербицидные соединения
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
WO2008060907A3 (en) Pyrrolo-pyridine kinase inhibitors
MY139942A (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
WO2007079164A3 (en) Protein kinase inhibitors
WO2007041130A3 (en) Deazapurines useful as inhibitors of janus kinases
MA29433B1 (fr) COMPOSES IMIDAZO[1,2-a]PYRIDINYLE INHIBITEURS DU VEGF-R2.
WO2006021884A3 (en) Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
EP1675552A4 (en) PREPARATION OF 1,6-DISUBSTITUTED AZABENIC ZIMIDAZOLES AS KINASE-INHIBITORS
GEP20115171B (en) Polymorphs of benzoate salt of 2-[[6-[(3r)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2h)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
TW200638934A (en) Heteroaryl compounds as P2Y1 receptor inhibitors
UA83875C2 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
WO2003028711A3 (en) Use of c-kit inhibitors for the treatment of myeloma
WO2008061108A3 (en) Phthalazine derivatives
MA30706B1 (fr) Derives du tartrate destines a etre utilises comme inhibiteurs du facteur de coagulation ixa.
WO2008049855A3 (en) 7-azaindole derivatives as c-met kinase inhibitors
WO2005115145A3 (en) Quinone substituted quinazoline and quinoline kinase inhibitors